CA2306086A1 - Use of thiazolidinediones for the treatment of hyperglycaemia - Google Patents

Use of thiazolidinediones for the treatment of hyperglycaemia Download PDF

Info

Publication number: CA2306086A1
Authority: CA; Canada
Prior art keywords: hyperglycaemia; range; glucose levels; plasma glucose; compound
Prior art date: 1997-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002306086A

Other languages

English (en)

French (fr)

Inventor

Robert Edwin Buckingham

Stephen Alistair Smith

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-13

Filing date

1998-10-12

Publication date

1999-04-22

1998-10-12 Application filed by Individual filed Critical Individual

1999-04-22 Publication of CA2306086A1 publication Critical patent/CA2306086A1/en

Status Abandoned legal-status Critical Current

Links

201000001421 hyperglycemia Diseases 0.000 title claims abstract description 40
238000011282 treatment Methods 0.000 title claims abstract description 14
229940123464 Thiazolidinedione Drugs 0.000 title claims description 10
150000001467 thiazolidinediones Chemical class 0.000 title description 3
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 72
102000004877 Insulin Human genes 0.000 claims abstract description 36
108090001061 Insulin Proteins 0.000 claims abstract description 36
229940125396 insulin Drugs 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims abstract description 34
231100000489 sensitizer Toxicity 0.000 claims abstract description 28
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 23
239000008103 glucose Substances 0.000 claims abstract description 23
241000124008 Mammalia Species 0.000 claims abstract description 5
231100000252 nontoxic Toxicity 0.000 claims abstract description 5
230000003000 nontoxic effect Effects 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 45
239000000203 mixture Substances 0.000 claims description 19
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 8
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
238000007410 oral glucose tolerance test Methods 0.000 claims description 5
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 5
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000012453 solvate Substances 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
229960001641 troglitazone Drugs 0.000 claims description 3
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 3
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims description 2
229950009226 ciglitazone Drugs 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
229950002375 englitazone Drugs 0.000 claims description 2
229960005095 pioglitazone Drugs 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
238000011321 prophylaxis Methods 0.000 description 5
230000002641 glycemic effect Effects 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
208000002705 Glucose Intolerance Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
201000009104 prediabetes syndrome Diseases 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
241000220479 Acacia Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010056997 Impaired fasting glucose Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
101150087654 chrnd gene Proteins 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002306086A 1997-10-13 1998-10-12 Use of thiazolidinediones for the treatment of hyperglycaemia Abandoned CA2306086A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9721693.1		1997-10-13
GBGB9721693.1A GB9721693D0 (en)	1997-10-13	1997-10-13	Novel treatment
PCT/GB1998/003064 WO1999018943A1 (en)	1997-10-13	1998-10-12	Use of thiazolidinediones for the treatment of hyperglycaemia

Publications (1)

Publication Number	Publication Date
CA2306086A1 true CA2306086A1 (en)	1999-04-22

Family

ID=10820482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002306086A Abandoned CA2306086A1 (en)	1997-10-13	1998-10-12	Use of thiazolidinediones for the treatment of hyperglycaemia

Country Status (24)

Country	Link
EP (1)	EP1023056A1 (id)
JP (1)	JP2001519382A (id)
KR (1)	KR20010024481A (id)
CN (1)	CN1281359A (id)
AP (1)	AP2000001787A0 (id)
AU (1)	AU9547098A (id)
BG (1)	BG104404A (id)
BR (1)	BR9815219A (id)
CA (1)	CA2306086A1 (id)
CZ (1)	CZ20001297A3 (id)
EA (1)	EA002659B1 (id)
GB (1)	GB9721693D0 (id)
HR (1)	HRP20000255A2 (id)
HU (1)	HUP0003922A3 (id)
ID (1)	ID24521A (id)
IL (1)	IL135513A0 (id)
NO (1)	NO20001898L (id)
NZ (1)	NZ503862A (id)
OA (1)	OA11683A (id)
PL (1)	PL339813A1 (id)
SK (1)	SK5312000A3 (id)
TR (1)	TR200000958T2 (id)
WO (1)	WO1999018943A1 (id)
YU (1)	YU28800A (id)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0842925A1 (en) *	1987-09-04	1998-05-20	Beecham Group Plc	Substituted thiazolidinedione derivatives
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
US5457109A (en) *	1993-09-15	1995-10-10	Warner-Lambert Company	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

1997
- 1997-10-13 GB GBGB9721693.1A patent/GB9721693D0/en not_active Ceased
1998
- 1998-10-12 BR BR9815219-0A patent/BR9815219A/pt not_active Application Discontinuation
- 1998-10-12 ID IDW20000669A patent/ID24521A/id unknown
- 1998-10-12 JP JP2000515578A patent/JP2001519382A/ja active Pending
- 1998-10-12 YU YU28800A patent/YU28800A/sh unknown
- 1998-10-12 AU AU95470/98A patent/AU9547098A/en not_active Abandoned
- 1998-10-12 NZ NZ503862A patent/NZ503862A/xx unknown
- 1998-10-12 HR HR20000255A patent/HRP20000255A2/hr not_active Application Discontinuation
- 1998-10-12 OA OA1200000108A patent/OA11683A/en unknown
- 1998-10-12 CN CN98812083A patent/CN1281359A/zh active Pending
- 1998-10-12 EP EP98949086A patent/EP1023056A1/en not_active Withdrawn
- 1998-10-12 CZ CZ20001297A patent/CZ20001297A3/cs unknown
- 1998-10-12 HU HU0003922A patent/HUP0003922A3/hu unknown
- 1998-10-12 IL IL13551398A patent/IL135513A0/xx unknown
- 1998-10-12 SK SK531-2000A patent/SK5312000A3/sk unknown
- 1998-10-12 WO PCT/GB1998/003064 patent/WO1999018943A1/en not_active Ceased
- 1998-10-12 PL PL98339813A patent/PL339813A1/xx unknown
- 1998-10-12 CA CA002306086A patent/CA2306086A1/en not_active Abandoned
- 1998-10-12 TR TR2000/00958T patent/TR200000958T2/xx unknown
- 1998-10-12 AP APAP/P/2000/001787A patent/AP2000001787A0/en unknown
- 1998-10-12 EA EA200000419A patent/EA002659B1/ru not_active IP Right Cessation
- 1998-10-12 KR KR1020007003934A patent/KR20010024481A/ko not_active Ceased
2000
- 2000-04-12 NO NO20001898A patent/NO20001898L/no not_active Application Discontinuation
- 2000-05-05 BG BG104404A patent/BG104404A/bg unknown

Also Published As

Publication number	Publication date
HRP20000255A2 (en)	2001-02-28
YU28800A (sh)	2003-02-28
HUP0003922A3 (en)	2001-12-28
IL135513A0 (en)	2001-05-20
CZ20001297A3 (cs)	2001-08-15
NO20001898L (no)	2000-06-09
NO20001898D0 (no)	2000-04-12
JP2001519382A (ja)	2001-10-23
CN1281359A (zh)	2001-01-24
AP2000001787A0 (en)	2000-06-30
GB9721693D0 (en)	1997-12-10
NZ503862A (en)	2003-01-31
ID24521A (id)	2000-07-20
TR200000958T2 (tr)	2000-08-21
SK5312000A3 (en)	2000-09-12
WO1999018943A1 (en)	1999-04-22
AU9547098A (en)	1999-05-03
BG104404A (bg)	2000-12-29
PL339813A1 (en)	2001-01-02
BR9815219A (pt)	2001-01-02
EA002659B1 (ru)	2002-08-29
EA200000419A1 (ru)	2000-10-30
HUP0003922A2 (hu)	2001-10-28
EP1023056A1 (en)	2000-08-02
OA11683A (en)	2005-01-12
KR20010024481A (ko)	2001-03-26

Legal Events

Date	Code	Title	Description
2003-10-07	EEER	Examination request
2007-07-19	FZDE	Discontinued

Publication	Publication Date	Title
AU8448898A (en)	1999-02-10	Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
CA2297115C (en)	2010-02-23	Treatment of diabetes with thiazolidinedione and sulphonylurea
CA2297133A1 (en)	1999-01-28	Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
CA2294134A1 (en)	1998-12-23	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
US20020137773A1 (en)	2002-09-26	Use of thiazolidinediones for the treatment of hyperglycaemia
US20030069283A1 (en)	2003-04-10	Use of thiazolidinediones for the treatment of hyperglycaemia
CA2305289A1 (en)	1999-04-22	Use of thiazolidinediones for the treatment of hyperglycaemia
CA2306086A1 (en)	1999-04-22	Use of thiazolidinediones for the treatment of hyperglycaemia
US20020045649A1 (en)	2002-04-18	Treatment of diabetes with thiazolidinedione and sulphonylurea
AU4586902A (en)	2002-08-01	Use of thiazolidinediones for the treatment of hyperglycaemia
AU4587002A (en)	2002-08-01	Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003633A (en)	2001-07-31	Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003634A (en)	2001-05-07	Use of thiazolidinediones for the treatment of hyperglycaemia
US20020123514A1 (en)	2002-09-05	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
CA2549864A1 (en)	1998-12-23	Treatment of diabetes with thiazolidinedione and metformin
MXPA99012078A (en)	2000-08-01	Treatment of diabetes with thiazolidinedione and metformin